UCB to Pay $2 Billion Upfront for Candid’s BCMA‑Targeting T‑Cell Engager

Context UCB is expanding its immunology portfolio through acquisitions that bring next‑generation biologics into its pipeline. Candid Therapeutics, a clinical‑stage biotech, focuses on multispecific T‑cell engager antibodies designed to redirect immune cells against disease‑relevant targets. Its lead candidate, cizutamig, binds B‑cell maturation antigen (BCMA) on plasma cells and CD3 on T‑cells, aiming to trigger targeted cell death while limiting cytokine release.

Key Facts - UCB will pay $2 billion upfront, with up to $200 million in milestone payments, for a total potential value of $2.2 billion. - The deal is slated to close at the end of Q2 or the start of Q3 2026, pending antitrust clearance and standard closing conditions. - Cizutamig has been evaluated in more than 100 patients across multiple myeloma and autoimmune disease studies and is currently in Phase I trials for over ten autoimmune indications (clinical trial identifier NCT07408869). - CEO Jean‑Christophe Tellier described the acquisition as a concrete step in UCB’s “inorganic innovation strategy,” adding a pivotal technology to its pipeline. - Candid’s broader pipeline includes additional T‑cell engager candidates targeting various disease mechanisms.

What It Means The upfront payment reflects UCB’s confidence that cizutamig could become a transformative therapy for severe, underserved immune‑mediated diseases. By acquiring a bispecific antibody platform, UCB diversifies beyond its existing monoclonal antibody programs and reduces reliance on a single modality. The Phase I data, derived from a cohort of over 100 patients, provide early safety and pharmacodynamic signals but do not establish efficacy; further trials will be needed to confirm clinical benefit.

For patients, the deal could accelerate development of a therapy that selectively eliminates pathogenic plasma cells while sparing broader immune function, potentially improving outcomes in conditions such as multiple myeloma and refractory autoimmune disorders. For investors, the $2 billion upfront outlay signals a high‑risk, high‑reward bet on a technology still in early clinical stages.

What to Watch Next Monitor the regulatory review timeline and the upcoming Phase II data from cizutamig’s autoimmune trials, which will indicate whether the asset can deliver on its promise and justify UCB’s sizable investment.